-
1
-
-
0035146344
-
Renal gluconeogenesis: Its importance in human glucose homeostasis
-
Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382-91.
-
(2001)
Diabetes Care
, vol.24
, pp. 382-391
-
-
Gerich, J.E.1
Meyer, C.2
Woerle, H.J.3
Stumvoll, M.4
-
2
-
-
79651473537
-
Renal glucose reabsorption inhibitors to treat diabetes
-
Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63-71.
-
(2011)
Trends Pharmacol Sci
, vol.32
, pp. 63-71
-
-
Bailey, C.J.1
-
3
-
-
80054108953
-
Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: A review of Phase II and III trials
-
Kipnes M. Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clin Investig. 2011;1:145-56.
-
(2011)
Clin Investig
, vol.1
, pp. 145-156
-
-
Kipnes, M.1
-
4
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors
-
Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
-
5
-
-
77957608196
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2), in healthy volunteers
-
Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2), in healthy volunteers. Diabetes. 2010;59(Suppl. 1):A155.
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Port, A.1
MacHa, S.2
Seman, L.3
-
6
-
-
79952991707
-
Safety and tolerability of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes
-
Seman L, Macha S, Jones P, et al. Safety and tolerability of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl. 1):A156.
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Seman, L.1
MacHa, S.2
Jones, P.3
-
7
-
-
19944427998
-
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
-
Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-51.
-
(2005)
J Med Chem
, vol.48
, pp. 141-151
-
-
Kim, D.1
Wang, L.2
Beconi, M.3
-
8
-
-
77957162913
-
-
Merck & Co, Inc. Whitehouse Station, NJ, USA
-
Januvia (sitagliptin) [package insert]. 2010; Merck & Co, Inc. Whitehouse Station, NJ, USA.
-
(2010)
Januvia (Sitagliptin) [Package Insert]
-
-
-
9
-
-
58149090676
-
The role of incretins in glucose homeostasis and diabetes treatment
-
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
-
(2008)
Pharmacol Rev
, vol.60
, pp. 470-512
-
-
Kim, W.1
Egan, J.M.2
-
10
-
-
32844473903
-
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
-
Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.
-
(2006)
Clin Ther
, vol.28
, pp. 55-72
-
-
Bergman, A.J.1
Stevens, C.2
Zhou, Y.3
-
11
-
-
28844482322
-
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
-
Herman GA, Stevens C, Van DK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675-88.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 675-688
-
-
Herman, G.A.1
Stevens, C.2
Van, D.K.3
-
12
-
-
64349083605
-
Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006
-
Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-53.
-
(2009)
Am J Med
, vol.122
, pp. 443-453
-
-
Cheung, B.M.1
Ong, K.L.2
Cherny, S.S.3
Sham, P.C.4
Tso, A.W.5
Lam, K.S.6
-
13
-
-
75549091263
-
Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control
-
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
-
(2009)
Endocr Pract
, vol.15
, pp. 540-559
-
-
Rodbard, H.W.1
Jellinger, P.S.2
Davidson, J.A.3
Einhorn, D.4
Garber, A.J.5
Grunberger, G.6
-
14
-
-
84867016516
-
-
12th Ed. Chantilly VA: MedDRA Maintenance And Support Services Organization
-
MedDRA Introductory Guide. 12th ed. Chantilly, VA: MedDRA Maintenance and Support Services Organization; 2009.
-
(2009)
MedDRA Introductory Guide
-
-
-
15
-
-
33947420172
-
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes
-
Gallwitz B. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:13-25.
-
(2007)
Drugs Today (Barc)
, vol.43
, pp. 13-25
-
-
Gallwitz, B.1
-
16
-
-
77958540127
-
Vildagliptin: A review of its use in type 2 diabetes mellitus
-
Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089-112.
-
(2010)
Drugs
, vol.70
, pp. 2089-2112
-
-
Keating, G.M.1
-
17
-
-
80051654526
-
Saxagliptin: A clinical review in the treatment of type 2 diabetes mellitus
-
Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:1005-22.
-
(2011)
Clin Ther
, vol.33
, pp. 1005-1022
-
-
Kania, D.S.1
Gonzalvo, J.D.2
Weber, Z.A.3
-
18
-
-
79953189076
-
Linagliptin: In type 2 diabetes mellitus
-
Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs. 2011;71:611-24.
-
(2011)
Drugs
, vol.71
, pp. 611-624
-
-
Scott, L.J.1
-
19
-
-
81855192456
-
Pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers
-
Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle H-J. Pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers. Diabetes. 2011;60(Suppl. 1):A616-7.
-
(2011)
Diabetes
, vol.60
, Issue.SUPPL. 1
-
-
Friedrich, C.1
Metzmann, K.2
Rose, P.3
Mattheus, M.4
Pinnetti, S.5
Woerle, H.-J.6
|